<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000763268"><TermName>Zydelig</TermName><TermPronunciation>(zy-DEH-lig)</TermPronunciation><TermDefinition><DefinitionText>A drug used with rituximab to treat chronic lymphocytic leukemia (CLL) that has come back. It is also used to treat follicular B-cell non-Hodgkin lymphoma (NHL) and small lymphocytic lymphoma (SLL) that have come back after treatment with other anticancer therapy. It is also being studied in the treatment of other types of cancer. Zydelig blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor. Also called idelalisib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000764443" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Zydelig&quot;" language="en" id="_3"/><MediaLink ref="CDR0000764442" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Zydelig&quot;" language="es" id="_4"/><SpanishTermName>Zydelig</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa junto con el rituximab en el tratamiento de la leucemia linfocítica crónica (LLC) que ha regresado. También se usa en el tratamiento del linfoma no Hodgkin (LNH) de células B folicular y  del linfoma linfocítico pequeño (LLP) que han regresado después de otros tratamientos contra el cáncer.  Zydelig impide la acción de ciertas proteínas que pueden evitar el crecimiento de ciertas células cancerosas y eliminarlas. Es un tipo de inhibidor  de la cinasa. También se llama idelalisib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2014-07-30</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000763259">Idelalisib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
